Atorvastatin reduces IOP in ocular hypertension in vivo and suppresses ECM in trabecular meshwork perhaps via FGD4

Int J Mol Med. 2022 Jun;49(6):76. doi: 10.3892/ijmm.2022.5132. Epub 2022 Apr 13.

Abstract

To explore the role of atorvastatin in regulating intraocular pressure (IOP) in glaucoma in vivo, and to investigate its related molecular pathway in vitro, an ocular hypertension model was generated by intravitreal injection of an adenoviral vector encoding transforming growth factor (TGF)‑β2 in the right eye of BALB/cJ mice, while the left was treated with an empty control adenovirus. To determine its anti‑intraocular hypertension role, these induced hyper‑IOP mice were gavaged with atorvastatin (20 mg/kg/day). Furthermore, extracellular matrix (ECM) factors were examined in the primary human trabecular meshwork (HTM) cells followed atorvastatin (0~200 µM) treatment in vitro. Whole genome microarray was employed to identify potential therapeutic target molecules associated with ECM regulation. Unilateral murine ocular hypertension was induced, via intravitreal injection of the adenoviral vector carrying the human TGF‑β2 gene (Ad.hTGF‑β2226/228), raising IOP from 12±1.6 to 32.3±0.7 mmHg (n=6, P<0.05) at day 15, which plateaued from day 15 to 30. Atorvastatin administration from day 15 to 30 decreased IOP from 32.3±0.7 to 15.4±1.1 mmHg (n=6, P<0.05) at day 30. Additionally, atorvastatin administration changed the morphology of cultured HTM cells from an elongated and adherent morphology into rounded, less elongated and less adherent cells, accompanied with suppressed expression of ECM. Gene Ontology and Genome analysis revealed that FGD4 (FYVE, RhoGEF and PH domain containing 4) might be a key factor contributing to these changes. Our data demonstrated that atorvastatin reduced TGF‑β2‑induced ocular hypertension in vivo, perhaps via modifying cellular structure and decreasing ECM, using the FGD4 signaling pathway, as demonstrated in HTM cells. Our findings provide some useful information for the management of glaucoma, with statin therapy revealing a potential novel therapeutic pathway for glaucoma treatment.

Keywords: FGD4; atorvastatin; extracellular matrix; ocular hypertension mouse model; primary human trabecular meshwork cells.

MeSH terms

  • Animals
  • Atorvastatin* / pharmacology
  • Cells, Cultured
  • Extracellular Matrix / metabolism
  • Glaucoma* / metabolism
  • Intraocular Pressure
  • Mice
  • Microfilament Proteins* / genetics
  • Ocular Hypertension* / chemically induced
  • Ocular Hypertension* / drug therapy
  • Ocular Hypertension* / metabolism
  • Trabecular Meshwork / metabolism
  • Transforming Growth Factor beta2 / pharmacology

Substances

  • Fgd4 protein, mouse
  • Microfilament Proteins
  • Transforming Growth Factor beta2
  • Atorvastatin

Grants and funding

This study was supported by the Science and Technology Commission of Shanghai Municipality (Technology project 18441901400)